2018
DOI: 10.3892/ijo.2018.4288
|View full text |Cite
|
Sign up to set email alerts
|

Simvastatin exerts anticancer effects in osteosarcoma cell lines via geranylgeranylation and c-Jun activation

Abstract: Osteosarcoma is the leading primary bone cancer in young adults and exhibits high chemoresistance rates. Therefore, characterization of both alternative treatment options and the underlying mechanisms is essential. Simvastatin, a cholesterol-lowering drug, has among its pleiotropic effects anticancer potential. Characterizing this potential and the underlying mechanisms in osteosarcoma is the subject of the present study. Human osteosarcoma cells (SaOS-2 and U2OS) were treated with simvastatin (4-66 µM) for 48… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
20
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 26 publications
(21 citation statements)
references
References 55 publications
0
20
0
Order By: Relevance
“…As statins have long been safely used to treat hypercholesterolemia and prevent cardiovascular diseases, they may hold promise as anti-metastatic treatment of cancers, in which YAP/TAZ play an important role [254]. In fact, simvastatin has been demonstrated to exert antimetastatic and cytotoxic effects in osteosarcoma [255,256], at least in part by the downregulation of YAP/TAZ/TEAD target genes CYR61 and CTGF [257,258]. It has also been shown to reactivate YAP-suppressed SOX9 in rat chondrosarcoma cells, leading to chondrocytic re-differentiation [259].…”
Section: Resultsmentioning
confidence: 99%
“…As statins have long been safely used to treat hypercholesterolemia and prevent cardiovascular diseases, they may hold promise as anti-metastatic treatment of cancers, in which YAP/TAZ play an important role [254]. In fact, simvastatin has been demonstrated to exert antimetastatic and cytotoxic effects in osteosarcoma [255,256], at least in part by the downregulation of YAP/TAZ/TEAD target genes CYR61 and CTGF [257,258]. It has also been shown to reactivate YAP-suppressed SOX9 in rat chondrosarcoma cells, leading to chondrocytic re-differentiation [259].…”
Section: Resultsmentioning
confidence: 99%
“…Statins have been extensively tested in humans, as they are widely used in hypercholesterolemia treatment. Moreover, previous observations in human and murine OS cells showed that statins sensitize OS cells to anticancer drugs and synergistically act with chemotherapeutic agents to reduce cell invasiveness [44,45]. Here, we focused on the role of prelamin A in statin-dependent effects.…”
Section: Discussionmentioning
confidence: 98%
“…The small sample size certainly limits the statistical power of the study. The study design and the sample size are based on previous in vitro studies from our group ( 22 , 50 ), and the observed significant results upon stimulation with cytokines as compared to unstimulated controls in the present study. Additionally, other relevant pro- and anti-inflammatory cytokines should be included in further analyses.…”
Section: Discussionmentioning
confidence: 99%